M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Colorectal Carcinoma
- Metastatic Lung Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Pancreatic Carcinoma
- Refractory Colorectal Carcinoma
- Refractory Lung Small Cell Carcinoma
- Refractory Malignant Solid Neoplasm
- Refractory Pancreatic Carcinoma
- Stage III Colorectal Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Colorectal Carcinoma
- Unresectable Lung Small Cell Carcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Pancreatic Carcinoma
Interventions
- DRUG: Berzosertib
- PROCEDURE: Biopsy Specimen
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- DRUG: Irinotecan Hydrochloride
Sponsor
National Cancer Institute (NCI)